In vitro leukemia cell models of Ara-C resistance

被引:24
作者
Funato, T
Satou, J
Nishiyama, Y
Fujimaki, S
Miura, T
Kaku, M
Sasaki, T
机构
[1] Tohoku Univ, Sch Med, Dept Mol Genet, Aoba Ku, Sendai, Miyagi 9808574, Japan
[2] Tohoku Univ, Sch Med, Dept Rheumatol & Hematol, Aoba Ku, Sendai, Miyagi 9808574, Japan
关键词
cytosine arabinoside (Ara-C); deoxycytidine kinase (dCK); human leukemia K562 cell; antisense oligonucleotides; drug resistance;
D O I
10.1016/S0145-2126(00)00016-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cells of the human leukemia line K562 were continuously exposed to cytosine arabinoside (Ara-C) at increasing concentrations for 3 months. The resulting cell line, termed K562/AC, showed 48-fold resistance to Ara-C, compared with the parental K562 cells. The sensitivities of K562/AC to adriamycin (ADR), vincristine (VCR) and etoposide (VP16) were similar to those of parental K562. Gene analysis revealed that this cell line lacked expression of the deoxycytidine kinase (dCK) gene, which was evident in Ara-C-sensitive cells. As in K562 cells, multidrug resistance (MDR-1) and multidrug resistance protein (MRP) genes were not expressed in K562/AC. We also established an in vitro model of Ara-C resistance using phosphorothioate antisense oligonucleotides to dCK (dCK-AS). Treatment of K562 with dCK-AS caused decreased dCK expression and 6- to 10-fold increases in resistance to Ara-C, compared with that in cells treated with sense oligonucleotides to dCK (dCK-S) or in non-transfected cells. The cells described here may contribute to the study of a novel mechanism associated with Ara-C resistance, in which reduced dCK activity may play an important role. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:535 / 541
页数:7
相关论文
共 26 条
[11]   LOW EXPRESSION OF THE DEOXYCYTIDINE KINASE (DCK) GENE IN A 1-BETA-D-ARABINOFURANOSYLCYTOSINE-RESISTANT HUMAN LEUKEMIC-CELL LINE KY-RA [J].
KOBAYASHI, T ;
KAKIHARA, T ;
UCHIYAMA, M ;
FUKUDA, T ;
KISHI, K ;
SHIBATA, A .
LEUKEMIA & LYMPHOMA, 1994, 15 (5-6) :503-505
[12]  
KUROSAWA M, 1996, ANN HEMATOL, V72, P7
[13]   QUANTIFYING C-MYC EXPRESSION IN C-MYC ANTISENSE PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDE-TREATED LEUKEMIC AND COLON-CANCER CELL-LINES [J].
LI, BDL ;
BUDNICK, RM ;
RUSSO, CA ;
ANDERSON, GR ;
STEWART, CC .
JOURNAL OF SURGICAL RESEARCH, 1995, 59 (04) :485-492
[14]  
MIRSKI SEL, 1987, CANCER RES, V47, P2594
[15]   OLIGONUCLEOTIDE PROBE DESIGN - A NEW APPROACH [J].
MITSUHASHI, M ;
COOPER, A ;
OGURA, M ;
SHINAGAWA, T ;
YANO, K ;
HOSOKAWA, T .
NATURE, 1994, 367 (6465) :759-761
[17]   Relation of blast cell survival and proliferation to chemotherapy resistance in AML [J].
Norgaard, JM ;
Langkjer, ST ;
Palshof, T ;
Clausen, N ;
Pedersen, B ;
Hokland, P .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 (04) :888-897
[18]  
OWENS JK, 1992, CANCER RES, V52, P2389
[19]   Multidrug-resistance drug-binding peptides generated by using a phage display library [J].
Popkov, M ;
Lussier, I ;
Medvedkine, V ;
Estève, PO ;
Alakhov, V ;
Mandeville, R .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1998, 251 (1-2) :155-163
[20]   INTRACELLULAR PHARMACODYNAMIC STUDIES OF THE SYNERGISTIC COMBINATION OF 6-MERCAPTOPURINE AND CYTOSINE-ARABINOSIDE IN HUMAN LEUKEMIA-CELL LINES [J].
RAMILOTORNO, LV ;
AVRAMIS, VI .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 35 (03) :191-199